Search

Your search keyword '"Bonderman, D"' showing total 345 results
Start Over Author "Bonderman, D"
345 results on '"Bonderman, D"'

2. Severe COVID-19 and its cardiopulmonary effects 6 and 18 months after hospital discharge

Author

Niebauer, J. H., primary, Iscel, A., additional, Schedl, S., additional, Capelle, C., additional, Kahr, M., additional, Schamilow, S., additional, Faltas, J., additional, Srdits, M., additional, Badr-Eslam, R., additional, Lichtenauer, M., additional, Zoufaly, A., additional, Valenta, R., additional, Hoffmann, S., additional, Charwat-Resl, S., additional, Krestan, C., additional, Hitzl, W., additional, Wenisch, C., additional, and Bonderman, D., additional

Published
2024
Full Text
View/download PDF

3. Myocardial structural and functional changes in cardiac amyloidosis - insights from a prospective observational patient registry

Author

Duca, F, primary, Rettl, R, additional, Binder, C, additional, Dachs, T M, additional, Camuz Ligios, L, additional, Agis, H, additional, Kain, R, additional, Koschutnik, M, additional, Dona, C, additional, Badr Eslam, R, additional, Nitsche, C, additional, Loewe, C, additional, Hengstenberg, C, additional, Kammerlander, A A, additional, and Bonderman, D, additional

Published
2023
Full Text
View/download PDF

4. Cardiopulmonary long-term impairment in patients 6 and 18 months post severe Covid-19 infection

Author

Niebauer, J H, primary, Iscel, A, additional, Schedl, S, additional, Capelle, C, additional, Kahr, M, additional, Schamilow, S, additional, Badr-Eslam, R, additional, Lichtenauer, M, additional, Zoufaly, A, additional, Valenta, R, additional, Charwat-Resl, S, additional, Krestan, C, additional, Hitzl, W, additional, Wenisch, C, additional, and Bonderman, D, additional

Published
2023
Full Text
View/download PDF

5. Monitoring patisiran and inotersen treatment with quantitative SPECT/CT in hereditary transthyretin amyloid cardiomyopathy

Author

Rettl, R, primary, Calabretta, R, additional, Duca, F, additional, Binder, C, additional, Kronberger, C, additional, Dona, C, additional, Beitzke, D, additional, Loewe, C, additional, Bonderman, D, additional, Hengstenberg, C, additional, Badr Eslam, R, additional, Kastner, J, additional, Bergler-Klein, J, additional, Hacker, M, additional, and Kammerlander, A A, additional

Published
2023
Full Text
View/download PDF

6. Diagnostic accuracy of amyloid scintigraphy for the histopathological diagnosis of cardiac transthyretin amyloidosis – a retrospective Austrian multicenter study

Author

Verheyen, N, primary, Ungericht, M, additional, Paar, L, additional, Danninger, K, additional, Schneiderbauer-Porod, S, additional, Duca, F, additional, Hoeller, V, additional, Ablasser, K, additional, Kiblboeck, D, additional, Frick, M, additional, Bonderman, D, additional, Dierneder, J, additional, Ebner, C, additional, Weber, T, additional, and Poelzl, G, additional

Published
2022
Full Text
View/download PDF

8. Two-dimensional speckle-tracking echocardiography in tafamidis-treated patients with transthyretin amyloid cardiomyopathy: a glimmer of hope for viable therapy monitoring?

Author

Rettl, R, primary, Duca, F, additional, Binder, C, additional, Dachs, T, additional, Cherouny, B, additional, Camuz Ligios, L, additional, Mann, C, additional, Schrutka, L, additional, Dalos, D, additional, Charwat-Resl, S, additional, Badr Eslam, R, additional, Kastner, J, additional, and Bonderman, D, additional

Published
2022
Full Text
View/download PDF

9. Neutrophile-lymphocyte ratio and outcome in takotsubo syndrome

Author

Zweiker, D, primary, Pogran, E, additional, Gargiulo, L, additional, El-Razek, A, additional, Vosko, I, additional, Rechberger, S, additional, Bugger, H, additional, Christ, G, additional, Bonderman, D, additional, Kunschitz, E, additional, Zirlik, A, additional, Bauer, A, additional, Metzler, B, additional, Steinwender, C, additional, and Huber, K, additional

Published
2022
Full Text
View/download PDF

10. Cardiopulmonary long-term effects in patients after hospitalization due to COVID-19 infection

Author

Niebauer, J, primary, Binder, C, additional, Iscel, A, additional, Klenk, S, additional, Capelle, C, additional, Kahr, M, additional, Cadjo, S, additional, Lichtenauer, M, additional, Toma, A, additional, Zoufaly, A, additional, Hoffman, S, additional, Charwat-Resl, S, additional, Krestan, C, additional, Wenisch, C, additional, and Bonderman, D, additional

Published
2022
Full Text
View/download PDF

14. A machine learning-derived electrocardiographic algorithm for the detection of cardiac amyloidosis

Author

Schrutka, L, primary, Anner, P, additional, Seirer, B, additional, Rettl, R, additional, Duca, F, additional, Dalos, D, additional, Dachs, T M, additional, Binder, C, additional, Badr-Eslam, R, additional, Kastner, J, additional, Loewe, C, additional, Hengstenberg, C, additional, Stix, G, additional, Dorffner, G, additional, and Bonderman, D, additional

Published
2021
Full Text
View/download PDF

16. Quantification of myocardial amyloid deposition in tafamidis-treated patients with transthyretin amyloid cardiomyopathy

Author

Rettl, R, primary, Wollenweber, T, additional, Mann, C, additional, Duca, F, additional, Dachs, T.-M, additional, Binder, C, additional, Stojanovic, M, additional, Camuz Ligios, L, additional, Schrutka, L, additional, Dalos, D, additional, Charwat-Resl, S, additional, Badr Eslam, R, additional, Kastner, J, additional, Hacker, M, additional, and Bonderman, D, additional

Published
2021
Full Text
View/download PDF

18. Cardiac imaging in tafamidis-treatment patients with transthyretin amyloid cardiomyopathy

Author

Rettl, R, primary, Mann, C, additional, Duca, F, additional, Dachs, T.-M, additional, Binder, C, additional, Kronberger, C, additional, Schrutka, L, additional, Dalos, D, additional, Dona, C, additional, Kammerlander, A, additional, Beitzke, D, additional, Charwat-Resl, S, additional, Kastner, J, additional, Badr Eslam, R, additional, and Bonderman, D, additional

Published
2021
Full Text
View/download PDF

19. Long-term cardiopulmonary effects after Covid-19 infection

Author

Niebauer, J H, primary, Binder- Rodriguez, C, additional, Iscel, A, additional, Klenk, S, additional, Badr-Eslam, R, additional, Cadjo, S, additional, Kahr, M, additional, Hoffman, S, additional, Reiter-Malqvist, S, additional, Boeck, R, additional, Wenisch, C, additional, Krestan, C, additional, Lichtenauer, M, additional, and Bonderman, D, additional

Published
2021
Full Text
View/download PDF

20. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Author

Teerlink, J.R. Diaz, R. Michael Felker, G. McMurray, J.J.V. Metra, M. Solomon, S.D. Adams, K.F. Anand, I. Arias-Mendoza, A. Biering-Sorensen, T. Bohm, M. Bonderman, D. Cleland, J.G.F. Corbalan, R. Crespo-Leiro, M.G. Dahlstrom, U. Echeverria, L.E. Fang, J.C. Filippatos, G. Fonseca, C. Goncalvesova, E. Goudev, A.R. Howlett, J.G. Lanfear, D.E. Li, J. Lund, M. Macdonald, P. Mareev, V. Momomura, S. O'Meara, E. Parkhomenko, A. Ponikowski, P. Ramires, F.J.A. Serpytis, P. Sliwa, K. Spinar, J. Suter, T.M. Tomcsanyi, J. Vandekerckhove, H. Vinereanu, D. Voors, A.A. Yilmaz, M.B. Zannad, F. Sharpsten, L. Legg, J.C. Varin, C. Honarpour, N. Abbasi, S.A. Malik, F.I. Kurtz, C.E.

Abstract

BACKGROUND The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro-B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016 -002299-28.). Copyright © 2020 Massachusetts Medical Society.

Published
2021

21. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Author

Teerlink, J. R., Diaz, R., Michael Felker, G., Mcmurray, J. J. V., Metra, M., Solomon, S. D., Adams, K. F., Anand, I., Arias-Mendoza, A., Biering-Sorensen, T., Bohm, M., Bonderman, D., Cleland, J. G. F., Corbalan, R., Crespo-Leiro, M. G., Dahlstrom, U., Echeverria, L. E., Fang, J. C., Filippatos, G., Fonseca, C., Goncalvesova, E., Goudev, A. R., Howlett, J. G., Lanfear, D. E., Li, J., Lund, M., Ambrosio, G., Carluccio, E., Macdonald, P., Mareev, V., Momomura, S., O'Meara, E., Parkhomenko, A., Ponikowski, P., Ramires, F. J. A., Serpytis, P., Sliwa, K., Spinar, J., Suter, T. M., Tomcsanyi, J., Vandekerckhove, H., Vinereanu, D., Voors, A. A., Yilmaz, M. B., Zannad, F., Sharpsten, L., Legg, J. C., Varin, C., Honarpour, N., Abbasi, S. A., Malik, F. I., Kurtz, C. E., and Cardiovascular Centre (CVC)

Subjects
Cardiac function curve, Male, medicine.medical_specialty, animal structures, Cardiotonic Agents, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Cardiac Myosins, Internal medicine, medicine, 80 and over, Humans, Urea, 030212 general & internal medicine, Aged, Aged, 80 and over, Heart Failure, Ejection fraction, business.industry, Cardiac myosin, Stroke Volume, General Medicine, Stroke volume, Middle Aged, medicine.disease, R1, Myocardial Contraction, 3. Good health, Omecamtiv mecarbil, Cardiovascular Diseases, Heart failure, cardiovascular system, Cardiology, Female, business, Heart Failure, Systolic, Systolic
Abstract

From: New England Journal of Medicine, Teerlink, JR, Diaz, R, Felker, G, et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure, 384(2):105-116. Copyright © 2020. Massachusetts Medical Society. Reprinted with permission. [Abstract] BACKGROUND. The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS. We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or 50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The primary outcome was a composite of a first heart-failure event (hospitalization or urgent visit for heart failure) or death from cardiovascular causes. RESULTS. During a median of 21.8 months, a primary-outcome event occurred in 1523 of 4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.86 to 0.99; P=0.03). A total of 808 patients (19.6%) and 798 patients (19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI, 0.92 to 1.11). There was no significant difference between groups in the change from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom score. At week 24, the change from baseline for the median N-terminal pro–B-type natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in the placebo group; the median cardiac troponin I level was 4 ng per liter higher. The frequency of cardiac ischemic and ventricular arrhythmia events was similar in the two groups. CONCLUSIONS. Among patients with heart failure and a reduced ejection, those who received omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event or death from cardiovascular causes than those who received placebo. (Funded by Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT number, 2016-002299-28.)

Published
2020
Full Text
View/download PDF

22. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

Author

Teerlink, J.R. Diaz, R. Felker, G.M. McMurray, J.J.V. Metra, M. Solomon, S.D. Adams, K.F. Anand, I. Arias-Mendoza, A. Biering-Sørensen, T. Böhm, M. Bonderman, D. Cleland, J.G.F. Corbalan, R. Crespo-Leiro, M.G. Dahlström, U. Echeverria Correa, L.E. Fang, J.C. Filippatos, G. Fonseca, C. Goncalvesova, E. Goudev, A.R. Howlett, J.G. Lanfear, D.E. Lund, M. Macdonald, P. Mareev, V. Momomura, S.-I. O'Meara, E. Parkhomenko, A. Ponikowski, P. Ramires, F.J.A. Serpytis, P. Sliwa, K. Spinar, J. Suter, T.M. Tomcsanyi, J. Vandekerckhove, H. Vinereanu, D. Voors, A.A. Yilmaz, M.B. Zannad, F. Sharpsten, L. Legg, J.C. Abbasi, S.A. Varin, C. Malik, F.I. Kurtz, C.E. GALACTIC-HF Investigators

Abstract

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials. Methods and results: Adults with established HFrEF, New York Heart Association (NYHA) functional class ≥II, ejection fraction ≤35%, elevated natriuretic peptides and either current hospitalization for heart failure or history of hospitalization/emergency department visit for heart failure within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic-guided dosing: 25, 37.5, or 50 mg bid). A total of 8256 patients [male (79%), non-white (22%), mean age 65 years] were enrolled with a mean ejection fraction 27%, ischaemic aetiology in 54%, NYHA class II 53% and III/IV 47%, and median N-terminal pro-B-type natriuretic peptide 1971 pg/mL. Heart failure therapies at baseline were among the most effectively employed in contemporary heart failure trials. GALACTIC-HF randomized patients representative of recent heart failure registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure

Published
2020

38. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Author

Galie, N, Humbert, M, Vachiery, J, Gibbs, S, Lang, I, Torbicki, A, Simonneau, G, Peacock, A, Vonk Noordegraaf, A, Beghetti, M, Ghofrani, A, Gomez Sanchez, M, Hansmann, G, Klepetko, W, Lancellotti, P, Matucci, M, Mcdonagh, T, Pierard, L, Trindade, P, Zompatori, M, Hoeper, M, Aboyans, V, Vaz Carneiro, A, Achenbach, S, Agewall, S, Allanore, Y, Asteggiano, R, Badano, L, Albert Barbera, J, Bouvaist, H, Bueno, H, Byrne, R, Carerj, S, Castro, G, Erol, C, Falk, V, Funck-Brentano, C, Gorenflo, M, Granton, J, Iung, B, Kiely, D, Kirchhof, P, Kjellstrom, B, Landmesser, U, Lekakis, J, Lionis, C, Lip, G, Orfanos, S, Park, M, Piepoli, M, Ponikowski, P, Revel, M, Rigau, D, Rosenkranz, S, Voller, H, Luis Zamorano, J, Myftiu, S, Bonderman, D, Firdovsi, I, Lazareva, I, De Pauw, M, Sokolovic, S, Velchev, V, Cikes, M, Moutiris, J, Jansa, P, Nielsen-Kudsk, J, Anton, L, Jaaskelainen, P, Bauer, F, Chukhrukidze, A, Opitz, C, Giannakoulas, G, Karlocai, K, Oddsson, O, Gaine, S, Menachemi, D, Emdin, M, Sooronbaev, T, Rudzitis, A, Gumbiene, L, Lebrun, F, Micallef, J, Botnaru, V, Oukerraj, L, Andreassen, A, Kurzyna, M, Leite Baptista, M, Coman, I, Moiseeva, O, Stefanovic, B, Simkova, I, Wikstrom, G, Schwerzmann, M, Srbinovska-Kostovska, E, van Dijk, A, Mahdhaoui, A, Kaymaz, C, Coghlan, G, Sirenko, Y, Galie N., Humbert M., Vachiery J. -L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., Ghofrani A., Gomez Sanchez M. A., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L. A., Trindade P. T., Zompatori M., Hoeper M., Aboyans V., Vaz Carneiro A., Achenbach S., Agewall S., Allanore Y., Asteggiano R., Badano L., Albert Barbera J., Bouvaist H., Bueno H., Byrne R. A., Carerj S., Castro G., Erol C., Falk V., Funck-Brentano C., Gorenflo M., Granton J., Iung B., Kiely D. G., Kirchhof P., Kjellstrom B., Landmesser U., Lekakis J., Lionis C., Lip G. Y. H., Orfanos S. E., Park M. H., Piepoli M. F., Ponikowski P., Revel M. -P., Rigau D., Rosenkranz S., Voller H., Luis Zamorano J., Myftiu S., Bonderman D., Firdovsi I., Lazareva I., De Pauw M., Sokolovic S., Velchev V., Cikes M., Moutiris J. A., Jansa P., Nielsen-Kudsk J. E., Anton L., Jaaskelainen P., Bauer F., Chukhrukidze A., Opitz C., Giannakoulas G., Karlocai K., Oddsson O., Gaine S., Menachemi D., Emdin M., Sooronbaev T., Rudzitis A., Gumbiene L., Lebrun F., Micallef J., Botnaru V., Oukerraj L., Andreassen A. K., Kurzyna M., Leite Baptista M. J. R., Coman I. M., Moiseeva O., Stefanovic B. S., Simkova I., Wikstrom G., Schwerzmann M., Srbinovska-Kostovska E., van Dijk A. P. J., Mahdhaoui A., Kaymaz C., Coghlan G., Sirenko Y., Galie, N, Humbert, M, Vachiery, J, Gibbs, S, Lang, I, Torbicki, A, Simonneau, G, Peacock, A, Vonk Noordegraaf, A, Beghetti, M, Ghofrani, A, Gomez Sanchez, M, Hansmann, G, Klepetko, W, Lancellotti, P, Matucci, M, Mcdonagh, T, Pierard, L, Trindade, P, Zompatori, M, Hoeper, M, Aboyans, V, Vaz Carneiro, A, Achenbach, S, Agewall, S, Allanore, Y, Asteggiano, R, Badano, L, Albert Barbera, J, Bouvaist, H, Bueno, H, Byrne, R, Carerj, S, Castro, G, Erol, C, Falk, V, Funck-Brentano, C, Gorenflo, M, Granton, J, Iung, B, Kiely, D, Kirchhof, P, Kjellstrom, B, Landmesser, U, Lekakis, J, Lionis, C, Lip, G, Orfanos, S, Park, M, Piepoli, M, Ponikowski, P, Revel, M, Rigau, D, Rosenkranz, S, Voller, H, Luis Zamorano, J, Myftiu, S, Bonderman, D, Firdovsi, I, Lazareva, I, De Pauw, M, Sokolovic, S, Velchev, V, Cikes, M, Moutiris, J, Jansa, P, Nielsen-Kudsk, J, Anton, L, Jaaskelainen, P, Bauer, F, Chukhrukidze, A, Opitz, C, Giannakoulas, G, Karlocai, K, Oddsson, O, Gaine, S, Menachemi, D, Emdin, M, Sooronbaev, T, Rudzitis, A, Gumbiene, L, Lebrun, F, Micallef, J, Botnaru, V, Oukerraj, L, Andreassen, A, Kurzyna, M, Leite Baptista, M, Coman, I, Moiseeva, O, Stefanovic, B, Simkova, I, Wikstrom, G, Schwerzmann, M, Srbinovska-Kostovska, E, van Dijk, A, Mahdhaoui, A, Kaymaz, C, Coghlan, G, Sirenko, Y, Galie N., Humbert M., Vachiery J. -L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., Ghofrani A., Gomez Sanchez M. A., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L. A., Trindade P. T., Zompatori M., Hoeper M., Aboyans V., Vaz Carneiro A., Achenbach S., Agewall S., Allanore Y., Asteggiano R., Badano L., Albert Barbera J., Bouvaist H., Bueno H., Byrne R. A., Carerj S., Castro G., Erol C., Falk V., Funck-Brentano C., Gorenflo M., Granton J., Iung B., Kiely D. G., Kirchhof P., Kjellstrom B., Landmesser U., Lekakis J., Lionis C., Lip G. Y. H., Orfanos S. E., Park M. H., Piepoli M. F., Ponikowski P., Revel M. -P., Rigau D., Rosenkranz S., Voller H., Luis Zamorano J., Myftiu S., Bonderman D., Firdovsi I., Lazareva I., De Pauw M., Sokolovic S., Velchev V., Cikes M., Moutiris J. A., Jansa P., Nielsen-Kudsk J. E., Anton L., Jaaskelainen P., Bauer F., Chukhrukidze A., Opitz C., Giannakoulas G., Karlocai K., Oddsson O., Gaine S., Menachemi D., Emdin M., Sooronbaev T., Rudzitis A., Gumbiene L., Lebrun F., Micallef J., Botnaru V., Oukerraj L., Andreassen A. K., Kurzyna M., Leite Baptista M. J. R., Coman I. M., Moiseeva O., Stefanovic B. S., Simkova I., Wikstrom G., Schwerzmann M., Srbinovska-Kostovska E., van Dijk A. P. J., Mahdhaoui A., Kaymaz C., Coghlan G., and Sirenko Y.

Abstract

Document Reviewers: Victor Aboyans (CPG Review Coordinator) (France), Antonio Vaz Carneiro (CPG Review Coordinator) (Portugal), Stephan Achenbach (Germany), Stefan Agewall (Norway), Yannick Allanore (France), Riccardo Asteggiano (Italy), Luigi Paolo Badano (Italy), Joan Albert Barbera (Spain), Helene Bouvaist (France), Hector Bueno (Spain), Robert A. Byrne (Germany), Scipione Carerj (Italy), Graca Castro (Portugal), Cetin Erol (Turkey), Volkmar Falk (Germany), Christian Funck-Brentano (France), Matthias Gorenflo (Germany), John Granton (Canada), Bernard Iung (France), David G. Kiely (UK), Paulus Kirchhof (Germany/UK), Barbro Kjellstrom (Sweden), Ulf Landmesser (Switzerland), John Lekakis (Greece), Christos Lionis (Greece), Gregory Y. H. Lip (UK), Stylianos E. Orfanos (Greece), Myung H. Park (USA), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marie-Pierre Revel (France), David Rigau (ERS methodologist) (Switzerland), Stephan Rosenkranz (Germany), Heinz Voller (Germany), and Jose Luis Zamorano (Spain)

Published
2016

39. P4669Quantification of fluid status using bioelectrical impedance spectroscopy (BIS): a predictor of outcome in patients with valvular heart disease

Author

Dona, C, primary, Kammerlander, A K, additional, Karner, B K, additional, Keil, A M, additional, Seitlhuber, M S, additional, Duca, F D, additional, Nitsche, C N, additional, Koschutnik, M K, additional, Binder, C B, additional, Aschauer, A S, additional, Bonderman, D B, additional, Hengstenberg, C H, additional, and Mascherbauer, J M, additional

Published
2019
Full Text
View/download PDF

41. P5261Feature tracking by CMR: left ventricular dysfunction predicts outcome in heart failure with preserved ejection fraction

Author

Kammerlander, A, primary, Kraiger, J, additional, Nitsche, C, additional, Dona, C, additional, Duca, F, additional, Zotter-Tufaro, C, additional, Binder, C, additional, Koschutnik, M, additional, Aschauer, S, additional, Loewe, C, additional, Hengstenberg, C, additional, Bonderman, D, additional, and Mascherbauer, J, additional

Published
2019
Full Text
View/download PDF

44. 131Left atrial phasic function in heart failure with preserved ejection fraction: cardiac magnetic resonance myocardial feature tracking, invasive hemodynamics and outcome

Author

Schoenbauer, R, primary, Kammerlander, A A, additional, Duca, F, additional, Aschauer, S, additional, Binder, C, additional, Zotter-Tufaro, C, additional, Nitsche, C, additional, Fiedler, L, additional, Roithinger, F X, additional, Loewe, C, additional, Hengstenberg, C, additional, Bonderman, D, additional, and Mascherbauer, J, additional

Published
2019
Full Text
View/download PDF

48. P139Feature tracking by cardiovascular magnetic resonance: left ventricular dysfunction predicts outcome in heart failure with preserved ejection fraction

Author

Kammerlander, A, primary, Karner, B, additional, Keil, A, additional, Seitlhuber, M, additional, Dona, C, additional, Nitsche, C, additional, Duca, F, additional, Beitzke, D, additional, Binder, C, additional, Koschutnik, M, additional, Aschauer, S, additional, Loewe, C, additional, Hengstenberg, C, additional, Bonderman, D, additional, and Mascherbauer, J, additional

Published
2019
Full Text
View/download PDF

49. 336Left atrial function in heart failure with preserved ejection fraction: backward and forward coupling and prognostic relevance

Author

Schoenbauer, R, primary, Kammerlander, A A, additional, Duca, F, additional, Aschauer, S, additional, Binder, C, additional, Zotter-Tufaro, C, additional, Nitsche, C, additional, Fiedler, L, additional, Roithinger, F X, additional, Loewe, C, additional, Hengstenberg, C, additional, Bonderman, D, additional, and Mascherbauer, J, additional

Published
2019
Full Text
View/download PDF

50. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Author

Galie N., Humbert M., Vachiery J. -L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., Ghofrani A., Gomez Sanchez M. A., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L. A., Trindade P. T., Zompatori M., Hoeper M., Aboyans V., Vaz Carneiro A., Achenbach S., Agewall S., Allanore Y., Asteggiano R., Badano L., Albert Barbera J., Bouvaist H., Bueno H., Byrne R. A., Carerj S., Castro G., Erol C., Falk V., Funck-Brentano C., Gorenflo M., Granton J., Iung B., Kiely D. G., Kirchhof P., Kjellstrom B., Landmesser U., Lekakis J., Lionis C., Lip G. Y. H., Orfanos S. E., Park M. H., Piepoli M. F., Ponikowski P., Revel M. -P., Rigau D., Rosenkranz S., Voller H., Luis Zamorano J., Myftiu S., Bonderman D., Firdovsi I., Lazareva I., De Pauw M., Sokolovic S., Velchev V., Cikes M., Moutiris J. A., Jansa P., Nielsen-Kudsk J. E., Anton L., Jaaskelainen P., Bauer F., Chukhrukidze A., Opitz C., Giannakoulas G., Karlocai K., Oddsson O., Gaine S., Menachemi D., Emdin M., Sooronbaev T., Rudzitis A., Gumbiene L., Lebrun F., Micallef J., Botnaru V., Oukerraj L., Andreassen A. K., Kurzyna M., Leite Baptista M. J. R., Coman I. M., Moiseeva O., Stefanovic B. S., Simkova I., Wikstrom G., Schwerzmann M., Srbinovska-Kostovska E., van Dijk A. P. J., Mahdhaoui A., Kaymaz C., Coghlan G., Sirenko Y., Galie, N, Humbert, M, Vachiery, J, Gibbs, S, Lang, I, Torbicki, A, Simonneau, G, Peacock, A, Vonk Noordegraaf, A, Beghetti, M, Ghofrani, A, Gomez Sanchez, M, Hansmann, G, Klepetko, W, Lancellotti, P, Matucci, M, Mcdonagh, T, Pierard, L, Trindade, P, Zompatori, M, Hoeper, M, Aboyans, V, Vaz Carneiro, A, Achenbach, S, Agewall, S, Allanore, Y, Asteggiano, R, Badano, L, Albert Barbera, J, Bouvaist, H, Bueno, H, Byrne, R, Carerj, S, Castro, G, Erol, C, Falk, V, Funck-Brentano, C, Gorenflo, M, Granton, J, Iung, B, Kiely, D, Kirchhof, P, Kjellstrom, B, Landmesser, U, Lekakis, J, Lionis, C, Lip, G, Orfanos, S, Park, M, Piepoli, M, Ponikowski, P, Revel, M, Rigau, D, Rosenkranz, S, Voller, H, Luis Zamorano, J, Myftiu, S, Bonderman, D, Firdovsi, I, Lazareva, I, De Pauw, M, Sokolovic, S, Velchev, V, Cikes, M, Moutiris, J, Jansa, P, Nielsen-Kudsk, J, Anton, L, Jaaskelainen, P, Bauer, F, Chukhrukidze, A, Opitz, C, Giannakoulas, G, Karlocai, K, Oddsson, O, Gaine, S, Menachemi, D, Emdin, M, Sooronbaev, T, Rudzitis, A, Gumbiene, L, Lebrun, F, Micallef, J, Botnaru, V, Oukerraj, L, Andreassen, A, Kurzyna, M, Leite Baptista, M, Coman, I, Moiseeva, O, Stefanovic, B, Simkova, I, Wikstrom, G, Schwerzmann, M, Srbinovska-Kostovska, E, van Dijk, A, Mahdhaoui, A, Kaymaz, C, Coghlan, G, and Sirenko, Y

Subjects
Endothelin receptor antagonist, Chronic thromboembolic pulmonary hypertension, Heart failure, Guideline, Prostacyclin analogue, Respiratory failure, Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension, Congenital heart disease, Connective tissue disease, Endothelin receptor antagonists, Guidelines, Heart failure, Left heart disease, Lung disease, Phosphodiesterase type 5 inhibitors, Prostacyclin analogues, Pulmonary arterial hypertension, Pulmonary hypertension, Respiratory failure, Pulmonary hypertension, Phosphodiesterase type 5 inhibitor, Left heart disease, Lung disease, Connective tissue disease, Congenital heart disease
Abstract

Document Reviewers: Victor Aboyans (CPG Review Coordinator) (France), Antonio Vaz Carneiro (CPG Review Coordinator) (Portugal), Stephan Achenbach (Germany), Stefan Agewall (Norway), Yannick Allanore (France), Riccardo Asteggiano (Italy), Luigi Paolo Badano (Italy), Joan Albert Barbera (Spain), Helene Bouvaist (France), Hector Bueno (Spain), Robert A. Byrne (Germany), Scipione Carerj (Italy), Graca Castro (Portugal), Cetin Erol (Turkey), Volkmar Falk (Germany), Christian Funck-Brentano (France), Matthias Gorenflo (Germany), John Granton (Canada), Bernard Iung (France), David G. Kiely (UK), Paulus Kirchhof (Germany/UK), Barbro Kjellstrom (Sweden), Ulf Landmesser (Switzerland), John Lekakis (Greece), Christos Lionis (Greece), Gregory Y. H. Lip (UK), Stylianos E. Orfanos (Greece), Myung H. Park (USA), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marie-Pierre Revel (France), David Rigau (ERS methodologist) (Switzerland), Stephan Rosenkranz (Germany), Heinz Voller (Germany), and Jose Luis Zamorano (Spain)

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results